ConductScience.org, home

Paper42477682

CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions.

Bach DH and 4 others. Cancer Cell Int, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions. Papers, record 42477682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42477682

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions.
PubMed
Journal
Cancer Cell Int
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-29
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bach DHDuc-Hiephttps://orcid.org/0000-0002-9826-3137
2Hoang VTVan T
3Huong PTVPham Thi Viet
4Nguyen DDDinh Duy
5Nguyen TLThanh Liem

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in42806364Correction: CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions.https://conductscience.org/library/papers/42806364

Source PubMed

Download CSV of comments and corrections

References133

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129385370Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med2018https://conductscience.org/library/papers/29385370PubMed
229226797Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.N Engl J Med2017https://conductscience.org/library/papers/29226797PubMed
336821768Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.Blood2023https://conductscience.org/library/papers/36821768PubMed
438374249FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers.Nat Rev Drug Discov2024https://conductscience.org/library/papers/38374249PubMed
533979178Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.J Clin Oncol2021https://conductscience.org/library/papers/33979178PubMed
636477031Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.N Engl J Med2022https://conductscience.org/library/papers/36477031PubMed
729686425Understanding the tumor immune microenvironment (TIME) for effective therapy.Nat Med2018https://conductscience.org/library/papers/29686425PubMed
825838376T cell exclusion, immune privilege, and the tumor microenvironment.Science2015https://conductscience.org/library/papers/25838376PubMed
929443960TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Nature2018https://conductscience.org/library/papers/29443960PubMed
1028187284Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.Cell2017https://conductscience.org/library/papers/28187284PubMed
1127433843Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.N Engl J Med2016https://conductscience.org/library/papers/27433843PubMed
1226205583Molecular and cellular insights into T cell exhaustion.Nat Rev Immunol2015https://conductscience.org/library/papers/26205583PubMed
1326321679Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.Cell2015https://conductscience.org/library/papers/26321679PubMed
1422437938Coordinated regulation of myeloid cells by tumours.Nat Rev Immunol2012https://conductscience.org/library/papers/22437938PubMed
1531359002Clonal replacement of tumor-specific T cells following PD-1 blockade.Nat Med2019https://conductscience.org/library/papers/31359002PubMed
1629033130Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.Cell2017https://conductscience.org/library/papers/29033130PubMed
1730610226Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.Nat Rev Drug Discov2019https://conductscience.org/library/papers/30610226PubMed
1825985798TRUCKs: the fourth generation of CARs.Expert Opin Biol Ther2015https://conductscience.org/library/papers/25985798PubMed
1927427982Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.J Clin Invest2016https://conductscience.org/library/papers/27427982PubMed
2027693353Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors.Cell2016https://conductscience.org/library/papers/27693353PubMed

See all 133 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
42806364Correction: CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions.Cancer Cell Int2026https://conductscience.org/library/papers/42806364

Source PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CXADRP1653108PubTator's text mininghttps://conductscience.org/library/genes/653108

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42477682

GET https://conductscience.org/api/papers/v1/42477682/references?page=2